NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2026)

NewAmsterdam Pharma has disclosed Other Non Operating Income across 4 years of filings, most recently posting -$5.9 million for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at -$5.9 million, up 56.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.2 million (up 91.95% YoY), and the FY2025 annual result was $22.8 million, down 40.97% from the prior year.
• Other Non Operating Income came in at -$5.9 million for Q1 2026 at NewAmsterdam Pharma, down from $15.3 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $30.2 million in Q1 2024 to a low of -$13.8 million in Q1 2025.
• The 4-year median for Other Non Operating Income is $3.1 million (2023), against an average of $4.8 million.
• Across the five-year window, Other Non Operating Income sank 1280.56% in 2024 and surged 967.81% in 2025, its largest moves.
• NewAmsterdam Pharma's Other Non Operating Income stood at $5.2 million in 2023, then surged by 275.14% to $19.6 million in 2024, then declined by 21.66% to $15.3 million in 2025, then slumped by 138.75% to -$5.9 million in 2026.
• The last three Other Non Operating Income figures came in at -$5.9 million (Q1 2026), $15.3 million (Q4 2025), and $218000.0 (Q3 2025), per Business Quant data.